Loading...
XNASRDUS
Market cap412mUSD
Jan 07, Last price  
14.77USD
1D
0.14%
1Q
-21.44%
Jan 2017
-42.53%
Name

Schnitzer Steel Industries Inc

Chart & Performance

D1W1MN
XNAS:RDUS chart
P/E
—
P/S
0.14
EPS
—
Div Yield, %
5.13%
Shrs. gr., 5y
-0.41%
Rev. gr., 5y
4.04%
Revenues
2.88b
-17.32%
688,220,000853,078,0001,854,715,0002,572,265,0003,641,550,0001,900,226,0002,301,240,0003,459,194,0003,340,938,0002,621,911,0002,543,583,0001,915,399,0001,352,543,0001,687,591,0002,364,715,0002,132,781,0001,712,343,0002,758,551,0003,485,815,0002,882,224,000
Net income
-26m
L
111,181,000146,867,000143,068,000131,334,000248,683,000-32,229,00066,750,000118,355,00027,404,000-281,442,0005,924,000-197,009,000-19,409,00044,511,000156,451,00056,345,000-2,105,000165,112,000168,800,000-25,791,000
CFO
139m
-41.36%
73,221,00073,499,000105,215,000179,315,000141,764,000287,579,00089,490,000140,463,000244,790,00039,289,000141,252,000144,628,00099,240,000100,370,000159,676,000144,740,000124,597,000190,064,000237,676,000139,362,000
Dividend
Jul 22, 20240.1875 USD/sh
Earnings
Apr 02, 2025

Profile

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
URL
https://www.schnitzersteel.com/
IPO date
Nov 16, 1993
Employees
3,471
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑082015‑08
Income
Revenues
2,882,224
-17.32%
3,485,815
26.36%
Cost of revenue
2,840,442
3,261,002
Unusual Expense (Income)
NOPBT
41,782
224,813
NOPBT Margin
1.45%
6.45%
Operating Taxes
(2,747)
44,597
Tax Rate
19.84%
NOPAT
44,529
180,216
Net income
(25,791)
-115.28%
168,800
2.23%
Dividends
(21,186)
(21,291)
Dividend yield
2.28%
2.18%
Proceeds from repurchase of equity
(34,248)
BB yield
3.51%
Debt
Debt current
25,648
27,701
Long-term debt
455,586
467,483
Deferred revenue
(5,583)
63,328
Other long-term liabilities
87,661
15,722
Net debt
464,452
438,540
Cash flow
Cash from operating activities
139,362
237,676
CAPEX
(129,516)
(150,121)
Cash from investing activities
(143,969)
(316,146)
Cash from financing activities
(33,132)
94,574
FCF
33,011
1,384
Balance
Cash
6,032
43,803
Long term investments
10,750
12,841
Excess cash
Stockholders' equity
885,624
935,499
Invested Capital
1,359,050
1,405,541
ROIC
3.22%
14.26%
ROCE
2.95%
15.31%
EV
Common stock shares outstanding
28,008
29,529
Price
33.20
0.48%
33.04
-30.16%
Market cap
929,866
-4.69%
975,638
-29.36%
EV
1,397,797
1,418,673
EBITDA
131,542
299,866
EV/EBITDA
10.63
4.73
Interest
18,589
8,538
Interest/NOPBT
44.49%
3.80%